Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 9:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 198 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Nicotinamide Placebo Clear all
Not yet recruiting Phase 2 Interventional

Nicotinamide Riboside Supplementation in Chronic Kidney Disease

NCT07693543
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Nicotinamide Riboside (NR), Matched Placebo (Capsules)
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
30 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 11, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy

NCT00493636
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine, Sorafenib, Placebo, Capecitabine
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
44
States / cities
Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 11, 2026, 9:23 AM EDT
Completed Not applicable Interventional Results available

Obesity and Nonalcoholic Fatty Liver Disease

NCT00262964
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Niacin, fenofibrate, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 11, 2026, 9:23 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children

NCT01237041
View directory record Official record
Conditions
Obesity, Short Stature, Growth Hormone Deficiency
Interventions
Niacin First, Placebo First, Dose-Establishing Study 1 Niacin 250mg, Dose-Establishing Study 1 Niacin 500mg, Dose-Establishing Study 2 Niacin 500mg
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 14 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 11, 2026, 9:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of NMN Supplementation on Organ System Biology

NCT04571008
View directory record Official record
Conditions
Glucose Metabolism Disorders
Interventions
Placebo, Treatment
Other · Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
45 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 11, 2026, 9:23 AM EDT
Not listed Phase 1Phase 2 Interventional

Tolerability and Efficacy of RJX in Patients With COVID-19

NCT04708340
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2, Hypoxemia
Interventions
Rejuveinix (RJX) Active Comparator, Placebo Comparator
Drug
Lead sponsor
Reven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Houston, Texas • New Braunfels, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 11, 2026, 9:23 AM EDT
Active, not recruiting Phase 2 Interventional

Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer

NCT05947383
View directory record Official record
Conditions
Cancer, Major Depressive Disorder
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Sunstone Medical
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 11, 2026, 9:23 AM EDT
Not listed Phase 2 Interventional

Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer

NCT00499525
View directory record Official record
Conditions
Breast Cancer
Interventions
paclitaxel, sorafenib tosylate, placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
43
States / cities
Muscle Shoals, Alabama • Fayetteville, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 11, 2026, 9:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of a Pre-Workout Dietary Supplement

NCT02952014
View directory record Official record
Conditions
Dietary Modification
Interventions
C4 Extreme, C4 Extreme (without Advantra Z, Placebo
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 40 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 11, 2026, 9:23 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults

NCT03821623
View directory record Official record
Conditions
Hypertension, Aging
Interventions
Nicotinamide riboside, Placebo
Drug · Other
Lead sponsor
Douglas Seals
Other
Eligibility
50 Years and older
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 11, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation

NCT00910962
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
GW856553, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
45 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
30
States / cities
Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 11, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Trial Evaluating Both Tolerability and Improvement for Signs of Facial Photoaging, Discoloration, and Texture in Adult Females of All Skin Types by Combining a Placebo Moisturizer and Non-ablative Laser.

NCT06090071
View directory record Official record
Conditions
Photoaging
Interventions
LaseMD Laser, Sciton Laser, Phyto A+ Brightening Treatment
Device · Drug
Lead sponsor
Austin Institute for Clinical Research
Network
Eligibility
25 Years to 70 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 11, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

NCT01338870
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, 25 mg PF-04991532, 75 mg PF-04991532, 150 mg PF-04991532, 300 mg PF-04991532, Sitagliptin 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Little Rock, Arkansas • Roseville, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Oct 11, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

NCT01004978
View directory record Official record
Conditions
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Interventions
Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Doxorubicin-Eluting Beads, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Mitomycin, Pharmacological Study, Placebo Administration, Sorafenib Tosylate
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
281
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 183 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 11, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer

NCT00073307
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
31
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 11, 2026, 9:23 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

NCT06032923
View directory record Official record
Conditions
Systemic Lupus Erythematosus (Sle)
Interventions
Nicotinamide Riboside
Dietary Supplement
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 120 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 11, 2026, 9:23 AM EDT
Completed Not applicable Interventional Results available

NAD+ and Exercise in FA

NCT04192136
View directory record Official record
Conditions
Friedreich Ataxia 1
Interventions
Nicotinamide Riboside, Placebo, Exercise Intervention
Dietary Supplement · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 40 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 11, 2026, 9:23 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+

NCT06919328
View directory record Official record
Conditions
Healthy Aging
Interventions
Niagen®, NAD+, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraceuticals Research Institute
Other
Eligibility
40 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 11, 2026, 9:23 AM EDT
Completed Not applicable Interventional Results available

Assessment Of Vascular Health After Niacin Therapy (AVANT)

NCT02003638
View directory record Official record
Conditions
Coronary Artery Disease, Carotid Artery Disease, Peripheral Artery Disease
Interventions
Niacin, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 11, 2026, 9:23 AM EDT
Terminated Phase 1Phase 2 Interventional

Nicotinamide Riboside for Diabetic Neuropathy

NCT03685253
View directory record Official record
Conditions
Diabetic Neuropathy Peripheral
Interventions
Niagen, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
30 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 11, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

NCT02066181
View directory record Official record
Conditions
Desmoid Fibromatosis
Interventions
Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Sorafenib Tosylate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
149
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Arroyo Grande, California + 79 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 11, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Topical Myristyl Nicotinate Cream on the Skin of Healthy Volunteers

NCT00619060
View directory record Official record
Conditions
Healthy
Interventions
Topical Myristyl Nicotinate Cream, Placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 11, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

NCT00600015
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Erlotinib + Sorafenib, Erlotinib + Placebo
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
Fort Myers, Florida • Gainesville, Georgia • Marietta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 11, 2026, 9:23 AM EDT
Terminated Phase 2 Interventional Results available

Sorafenib for Hepatopulmonary Syndrome

NCT02021929
View directory record Official record
Conditions
Hepatopulmonary Syndrome
Interventions
Sorafenib, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
7
States / cities
Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 11, 2026, 9:23 AM EDT